Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company focused on oncology, announced that its President and Chief Executive Officer, Abizer Gaslightwala, will be a speaker at the H.C. Wainwright 27th Annual Global Investment Conference. The conference will take place in New York, NY from September 8th to 10th.
In addition to the presentation, Akari‘s management team will conduct individual meetings with investors registered for the conference. Interested parties can find more information about the conference on its official website.
A recording of Mr. Gaslightwala‘s presentation will be accessible online. The webcast will be available on demand beginning September 5th, 2025, at 7:00 AM ET for registered attendees. It will also be archived on the company’s investor relations page at akaritx.com for three months following the event.
Akari Therapeutics develops next-generation antibody-drug conjugates (ADCs) for cancer treatment. The company uses a proprietary platform to create and optimize ADC candidates for various targets.
Their lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells. It employs a novel payload, PH1, a spliceosome modulator, designed to disrupt RNA splicing in cancer cells. This mechanism differs from current ADCs that use tubulin inhibitors or DNA-damaging agents.
Preclinical tests indicate that AKTX-101 induces cancer cell death while activating the immune system. Results showed significant activity and extended survival compared to ADCs with traditional payloads. Furthermore, AKTX-101 shows potential synergy with checkpoint inhibitors, demonstrating extended survival both as a single agent and in combination therapy.
Akari is currently generating data to support the development of AKTX-101 and other undisclosed programs utilizing the PH1 payload. Further information about the company can be found on its website and social media platforms. Investors can contact JTC Team, LLC for investor relations inquiries.
Related
